Ceftriaxone
Parkinson's Disease Dementia
BrainX CorporationSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Parkinson's Disease Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Namenda H. Lundbeck A/S | Phase 4 | BB |
Rivastigmine Novartis | Phase 3 | BB |
INTEPIRDINE Axovant Sciences Ltd. | Phase 2 | B |
PBR28 Columbia University | Phase 2 | B |
Ambroxol London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 | CCC |
Nelotanserin Axovant Sciences Ltd. | Phase 2 | CCC |
Nilotinib Georgetown University | Phase 1 | CC |
Same molecule, other indications
Ceftriaxone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →